UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019893
Receipt number R000022856
Scientific Title Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer
Date of disclosure of the study information 2015/11/24
Last modified on 2015/11/14 15:30:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer

Acronym

Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer

Scientific Title

Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer

Scientific Title:Acronym

Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer

Region

Japan


Condition

Condition

Metastatic colorectal cancer

Classification by specialty

Gastroenterology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

To evaluate the efficacy and safety of Cetuximab and Irinotecan as third-line treatment in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Response rate

Key secondary outcomes

Progression free survival
Overall survival
Pharmacokinetic parameter
Safety profile


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Cetuximab 500 mg/M2/2week
Irinotecan 150 mg/M2/2week

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

Written IC.
Pathologically diagnosed colorectal adenocarcinoma.
Unresectable colorectal cancer.
No KRAS mutation (codon 12 or codon13).
Age over 20 years old and under 75 years.
ECOG PS0-2.
Target lesion(RECIST 1.0).
Previously treated within 2 regimens and
Wihtout cetuximab. at least 2 week rest.
2 months or longer expected survival.
Adequate organ function.

Key exclusion criteria

Receive blood infusion, G-CSF within 7days before primary registration.
UGT1A1*28 homo, *6 homo,*28*6
Severe heart disease.
Severe liver disease.
Severe lung disease.
Active gastrointestinal bleeding.
Severe mental disease.
Severe diabetes.
Ileus.
Active infectious disease.
Other active cancer.
Cerebral metastasis.
Icterus .
Severe diarrhea.
Severe allergic reaction for drugs (irinotecan anti-EGFR antibody).
Massive ascites, plerural effusion.
Under treatment with atazanavir.
Past history of treatment with EGFR antibody.
Alcoholic or drug Intoxication.
Hbs antibody positive.
HCV antibody positive.
HIV antibody positive.
A pregnant woman, a woman in breast-feeding, a man who expects his baby.
An inappropriate case judged by docter in charge.

Target sample size

35


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Nobuyuki Mizunuma

Organization

The Cancer Institute Hospital, Japanese Foundation for Cancer Research

Division name

Department of Gastroenterology

Zip code


Address

3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan

TEL

03-3520-0111

Email

nobuyuki.mizunuma@jfcr.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Eiji Shinozaki

Organization

The Cancer Institute Hospital, Japanese Foundation for Cancer Research

Division name

Department of Gastroenterology

Zip code


Address

3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan

TEL

03-3520-0111

Homepage URL


Email

eiji.shinozaki@jfcr.or.jp


Sponsor or person

Institute

The Cancer Institute Hospital, Japanese Foundation for Cancer Research

Institute

Department

Personal name



Funding Source

Organization

The Cancer Institute Hospital, Japanese Foundation for Cancer Research

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

がん研有明病院 (東京都)


Other administrative information

Date of disclosure of the study information

2015 Year 11 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 06 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 10 Month 24 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 11 Month 22 Day

Last modified on

2015 Year 11 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022856


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name